Eur J Surg Oncol. 2025 Sep 2;51(11):110426. doi: 10.1016/j.ejso.2025.110426. Online ahead of print.
ABSTRACT
BACKGROUND: The Toumai® surgical robot, a cutting-edge medical assistance robot, was developed and launched in China.
OBJECTIVE: Compare the effectiveness and safety of the da Vinci robotic surgical system and the Toumai® surgical robot in RARP and RAPN surgeries(the Toumai® -RARP versus the DV-RARP, the Toumai®-RAPN versus the DV-RAPN).
DESIGN, SETTING, AND PARTICIPANTS: One randomized controlled trials were conducted among patients aged 18-77 years suspected of having T1a N0M0 renal cancer, and another randomized controlled trial was conducted among patients aged 55-79 years suspected of having T2 N0M0 prostate cancer.
REASULTS: The clinical characteristics of the two groups of patients undergoing the same surgical procedure showed no significant differences. All surgeries were successfully completed without the need for conversion from laparoscopic to open surgery. The operative time in the Toumai® group was significantly longer. Additionally, there were no significant differences between the two groups in key indicators such as blood loss, length of hospital stay, complication rates, and functional outcomes.
CONCLUSIONS: This comparative study on the efficacy and safety between the Toumai® system and the da Vinci system demonstrates that the Toumai® surgical robot and the da Vinci robotic system achieve comparable safety profiles, surgical outcomes, and postoperative expectations when performing RAPN and RARP procedures, with no statistically significant differences observed.
PMID:40966817 | DOI:10.1016/j.ejso.2025.110426
